Preface |
|
v | |
Contributors |
|
xvii | |
|
Advances in our Understanding of Neurodegeneration |
|
|
1 | (58) |
|
|
|
1 | (1) |
|
Basic processes common to neurodegeneration |
|
|
1 | (35) |
|
Neuronal death---the final pathway |
|
|
36 | (2) |
|
Challenges of apoptosis in neurodegeneration |
|
|
38 | (4) |
|
|
42 | (1) |
|
|
43 | (16) |
|
Mitochondrial Mutagenesis in the Brain in Forensic and Pathological Research |
|
|
59 | (30) |
|
|
|
59 | (1) |
|
Mitochondrial DNA damage and repair |
|
|
60 | (10) |
|
|
70 | (3) |
|
MT DNA mutagenesis in the brain |
|
|
73 | (6) |
|
|
79 | (10) |
|
Genetic and Environmental Factors in Neurodegenerative Diseases |
|
|
89 | (26) |
|
|
|
Causative genes in neurodegeneration |
|
|
89 | (3) |
|
Environmental factors and neurodegeneration |
|
|
92 | (4) |
|
Susceptibility genes in neurodegeneration |
|
|
96 | (2) |
|
|
98 | (5) |
|
|
103 | (2) |
|
|
105 | (1) |
|
|
106 | (1) |
|
|
107 | (8) |
|
Nitric Oxide and Cellular Stress Response in Brain Aging and Neurodegenerative Disorders |
|
|
115 | (20) |
|
|
|
|
Anna Maria Giuffrida Stella |
|
|
|
|
115 | (1) |
|
|
116 | (4) |
|
|
120 | (7) |
|
Conclusions and perspectives |
|
|
127 | (1) |
|
|
128 | (1) |
|
|
128 | (7) |
|
Oxidative Stress and Radiation-Induced Late Normal Tissue Injury |
|
|
135 | (30) |
|
|
|
|
135 | (1) |
|
Radiation-induced late effects |
|
|
136 | (5) |
|
Reactive oxygen/nitrogen oxide species (ROS/RNOS) |
|
|
141 | (2) |
|
Radiation-induced increase in ROS/RNOS generation |
|
|
143 | (1) |
|
The role of oxidative stress in radiation-induced late effects |
|
|
144 | (4) |
|
Treatment of radiation-induced late injury with RAS blockade |
|
|
148 | (3) |
|
Putative mediators of chronic oxidative stress: Ang II and ionizing radiation |
|
|
151 | (1) |
|
|
152 | (1) |
|
|
152 | (13) |
|
The Cell Cycle and Oxidative Neuronal Cell Death |
|
|
165 | (18) |
|
|
|
165 | (1) |
|
The terminally differentiated neuron and the cell division |
|
|
166 | (1) |
|
The cell cycle and checkpoint function |
|
|
167 | (2) |
|
Cell cycle regulators and neurodegeneration |
|
|
169 | (4) |
|
Oxidative stress induction of the cell cycle |
|
|
173 | (1) |
|
Is the cell cycle required for oxidative stress-induced death? |
|
|
174 | (1) |
|
|
175 | (2) |
|
|
177 | (1) |
|
|
177 | (6) |
|
|
183 | (18) |
|
|
Introduction: free radicals and oxidative stress |
|
|
183 | (1) |
|
Factors contributing to the generation of oxidative stress (OS) |
|
|
184 | (4) |
|
Interaction of ROS with genetic influences, protein aggregation and Lewy bodies (LBS) |
|
|
188 | (1) |
|
Mitochondrial dysfunction |
|
|
189 | (2) |
|
Consequences of redox imbalance |
|
|
191 | (1) |
|
Conclusion and therapeutic outlook |
|
|
192 | (1) |
|
|
193 | (8) |
|
Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies |
|
|
201 | (18) |
|
|
|
|
|
|
201 | (1) |
|
|
202 | (2) |
|
|
204 | (6) |
|
Human post-mortem PD subjects |
|
|
210 | (5) |
|
|
215 | (1) |
|
|
215 | (1) |
|
|
215 | (4) |
|
Down Syndrome, Antioxidant Balance and the ``Gene Dosage Effect'' Hypothesis |
|
|
219 | (18) |
|
|
|
|
|
|
219 | (1) |
|
Analysis of the HSA21 gene, Cu/Zn-superoxide dismutase-1 (SOD1) and its relationship to the antioxidant pathway |
|
|
220 | (3) |
|
Evidence for the involvement of an altered antioxidant pathway in Down syndrome (DS) |
|
|
223 | (6) |
|
Conclusions/discussion and future directions for therapeutic interventions |
|
|
229 | (1) |
|
|
230 | (7) |
|
The Role of Levodopa in the Chronic Neurodegenerative Disorder---Parkinson's Disease |
|
|
237 | (10) |
|
|
|
237 | (1) |
|
|
237 | (1) |
|
|
238 | (1) |
|
|
239 | (1) |
|
Levodopa-induced elevation of homocysteine |
|
|
240 | (1) |
|
Therapy of increased homocysteine levels in PD patients |
|
|
241 | (1) |
|
Is levodopa administration toxic in clinical practice? |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
243 | (4) |
|
Reactive Oxygen Metabolites (ROMs) as an Index of Oxidative Stress in Obstructive Sleep Apnea Patients |
|
|
247 | (20) |
|
|
|
Obstructive sleep apnea (OSA) syndrome |
|
|
247 | (4) |
|
Oxidation and reduction---pro-oxidants and antioxidants |
|
|
251 | (4) |
|
Hypoxia/reoxygenation injury (H/R) |
|
|
255 | (2) |
|
|
257 | (1) |
|
|
258 | (1) |
|
|
259 | (8) |
|
The Key Role of Oxidative Stress in Alzheimer's Disease |
|
|
267 | (16) |
|
|
|
|
|
|
|
|
|
|
267 | (1) |
|
Energetic metabolism deficiency in Alzheimer's disease |
|
|
268 | (1) |
|
Oxidative stress in Alzheimer's disease |
|
|
269 | (2) |
|
Sources of oxidative stress in Alzheimer's disease |
|
|
271 | (2) |
|
Alzheimer's disease lesions: cause or consequence of oxidative stress? |
|
|
273 | (3) |
|
|
276 | (1) |
|
|
276 | (7) |
|
The Role of Oxidative Stress in the Pathogenesis of Multiple Sclerosis: Current State |
|
|
283 | (14) |
|
|
|
|
|
|
283 | (1) |
|
Oxidative stress in the CNS |
|
|
284 | (1) |
|
Oxidative stress and inflammation |
|
|
284 | (2) |
|
|
286 | (2) |
|
Antioxidants as possible treatment for MS |
|
|
288 | (1) |
|
|
289 | (1) |
|
|
290 | (1) |
|
Concluding remarks and future strategies |
|
|
291 | (1) |
|
|
291 | (6) |
|
Oxidative Stress and Neuroinflammation in Alzheimer's Disease and Amyotrophic Lateral Sclerosis: From Biology to Therapeutic Strategies |
|
|
297 | (16) |
|
|
|
Neuroinflammation---a common feature of most age-related neurodegenerative diseases |
|
|
297 | (1) |
|
Neuroinflammation and Alzheimer's disease |
|
|
297 | (1) |
|
Anti-amyloidogenic properties of NSAIDs---a novel mechanism of action |
|
|
298 | (1) |
|
Mechanism underlying the reduction in Aβ generation by NSAIDs |
|
|
299 | (1) |
|
NSAIDs and clinical trials |
|
|
299 | (5) |
|
Antioxidant treatment and Alzheimer's disease |
|
|
304 | (1) |
|
Antioxidant clinical trials using Alzheimer's disease patients |
|
|
304 | (1) |
|
Neuroinflammation, oxidative stress, and ALS |
|
|
305 | (1) |
|
|
305 | (1) |
|
|
306 | (1) |
|
|
306 | (7) |
|
Oxidative Stress in Stroke |
|
|
313 | (56) |
|
|
|
|
313 | (30) |
|
Therapeutic strategies with antioxidants in acute and chronic phases after stroke |
|
|
343 | (12) |
|
|
355 | (1) |
|
|
356 | (13) |
|
Hyperoxidation of the Two Catecholamines, Dopamine and Adrenaline: Implications for the Etiologies and Treatment of Encephalitis Lethargica, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Schizophrenia |
|
|
369 | (14) |
|
|
|
|
369 | (6) |
|
Adrenaline and adrenochrome |
|
|
375 | (4) |
|
|
379 | (1) |
|
|
379 | (4) |
|
The Role of Metals and their Effect on Oxidative Stress in Amyotrophic Lateral Sclerosis |
|
|
383 | (16) |
|
|
|
|
383 | (1) |
|
|
384 | (3) |
|
Copper homeostasis and ALS |
|
|
387 | (3) |
|
|
390 | (2) |
|
Copper and iron: the devil's pair? |
|
|
392 | (1) |
|
|
393 | (1) |
|
|
393 | (6) |
|
Neurotransmission, Oxidative Stress, and Coexistence of Neurotransmitters in Parkinson's Disease |
|
|
399 | (34) |
|
|
|
399 | (3) |
|
|
402 | (22) |
|
|
424 | (1) |
|
|
425 | (8) |
|
Manganese-Induced Oxidative Stress |
|
|
433 | (18) |
|
|
|
|
433 | (1) |
|
|
434 | (1) |
|
Essentiality, absorption, and transport |
|
|
434 | (4) |
|
|
438 | (2) |
|
Manganese-induced oxidative stress |
|
|
440 | (3) |
|
|
443 | (8) |
|
Prospects for Antioxidant Therapy in Mild Cognitive Impairment and Alzheimer's Disease |
|
|
451 | (16) |
|
|
|
|
|
451 | (1) |
|
The early involvement of oxidative stress in the pathogenesis of AD |
|
|
452 | (3) |
|
Anti-oxidative strategy for AD: lessons from vitamin E studies |
|
|
455 | (3) |
|
Anti-oxidative strategy for AD: targeting modifiable risk factors |
|
|
458 | (2) |
|
|
460 | (1) |
|
|
460 | (7) |
|
An Assessment of the Chances of Antiapoptotic Drug Therapy in Patients with Neurodegenerative Disorders |
|
|
467 | (36) |
|
|
Apoptosis and other modes of cell death |
|
|
467 | (6) |
|
Evidence for a role of PCD in ND |
|
|
473 | (8) |
|
Development of antiapoptotic drugs for the treatment of neurodegenerative diseases (ND) |
|
|
481 | (1) |
|
The first two antiapoptotic compounds failed in clinical trials |
|
|
481 | (9) |
|
|
490 | (2) |
|
|
492 | (11) |
|
Role of Antioxidant Activity of Estrogens in their Potent Neuroprotection |
|
|
503 | (22) |
|
|
|
|
|
503 | (10) |
|
|
513 | (1) |
|
|
513 | (12) |
|
Diet, Herbs, and Nutritional Protection against Oxidative Stress in Neurological Diseases |
|
|
525 | (18) |
|
Carlos Kusano Bucalen Ferrari |
|
|
|
525 | (11) |
|
|
536 | (1) |
|
|
536 | (7) |
|
Diabetic Neuropathy: Pathogenesis and Treatment |
|
|
543 | (38) |
|
|
|
|
|
543 | (11) |
|
Treatment of diabetic neuropathy |
|
|
554 | (12) |
|
Neurosensory testing in diabetic neuropathy |
|
|
566 | (6) |
|
|
572 | (9) |
|
Green and Black Tea in Brain Protection |
|
|
581 | (26) |
|
|
|
|
|
|
581 | (19) |
|
|
600 | (7) |
|
Environmental and Genetic Interactions: Key to Sporadic Parkinson's Disease? |
|
|
607 | (14) |
|
|
|
|
607 | (7) |
|
|
614 | (1) |
|
|
615 | (1) |
|
|
616 | (5) |
|
Prevention and Therapy of Neurodegenerative Disorders: Role of Nutritional Antioxidants |
|
|
621 | (42) |
|
|
|
|
|
Major neurodegenerative disorders |
|
|
621 | (4) |
|
Natural dietary antioxidants |
|
|
625 | (8) |
|
ROS, NF-KB, and neurodegenerative disorders |
|
|
633 | (2) |
|
Alzheimer's disease, oxidative stress, NF-KB, and antioxidants |
|
|
635 | (3) |
|
Parkinson's disease, oxidative stress, NF-KB, and antioxidants |
|
|
638 | (4) |
|
Amyotrophic lateral sclerosis, oxidative stress, NF-KB, and antioxidants |
|
|
642 | (2) |
|
|
644 | (1) |
|
|
645 | (1) |
|
|
646 | (17) |
|
Genetics of Parkinson's Disease |
|
|
663 | (36) |
|
|
|
|
|
663 | (2) |
|
Causative genes for familial PD |
|
|
665 | (10) |
|
Susceptibility genes for PD |
|
|
675 | (12) |
|
Genetic implications for PD |
|
|
687 | (1) |
|
|
687 | (1) |
|
|
688 | (11) |
|
Biomarkers of Hypoxic Brain Injury |
|
|
699 | (20) |
|
|
|
|
|
|
699 | (11) |
|
|
710 | (1) |
|
|
711 | (8) |
|
Role of Selenium, Iron, Copper, and Zinc in Parkinsonism |
|
|
719 | (18) |
|
|
|
|
|
719 | (2) |
|
|
721 | (1) |
|
|
722 | (1) |
|
|
723 | (8) |
|
|
731 | (6) |
|
Oxidative Stress in Phagocytic Cells: Changes with Age and Effect of Melatonin |
|
|
737 | (26) |
|
|
|
|
|
|
|
|
|
|
737 | (7) |
|
Pinealectomy, bursectomy, and the immune system |
|
|
744 | (12) |
|
Conclusions: future horizon |
|
|
756 | (1) |
|
|
757 | (6) |
Index |
|
763 | |